Puma Biotechnology für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1J643 / ISIN: US74587V1070

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Puma Biotechnology Inc

11.12.20		Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS (Businesswire)
10.12.20		Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS (Businesswire)
09.12.20		Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 (Businesswire)
02.12.20		Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted (Businesswire)
17.11.20		Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS) (Businesswire)
06.11.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.11.20		Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer (Businesswire)
05.11.20		Puma Biotechnology Reports Third Quarter 2020 Financial Results (Businesswire)
03.11.20		Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference (Businesswire)
22.10.20		Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Businesswire)
05.10.20		Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer (Businesswire)
02.10.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
08.09.20		Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference (Businesswire)
03.09.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
19.08.20		Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology (Businesswire)
10.08.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
06.08.20		Puma Biotechnology Reports Second Quarter 2020 Financial Results (Businesswire)
27.07.20		Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers (Businesswire)
23.07.20		Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results (Businesswire)
09.07.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
02.06.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
08.05.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
07.05.20		Puma Biotechnology Reports First Quarter 2020 Financial Results (Businesswire)
06.05.20		Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020 (Businesswire)
30.04.20		Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea (Businesswire)
23.04.20		Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results (Businesswire)
03.04.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
25.03.20		Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.03.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.02.20		Puma Biotechnology to Present at Cowen’s Annual Health Care Conference (Businesswire)
26.02.20		Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer (Businesswire)
20.02.20		Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results (Businesswire)
07.02.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.02.20		Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results (Businesswire)
13.01.20		Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference (Businesswire)
09.01.20		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
07.01.20		Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference (Businesswire)
16.12.19		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
14.12.19		Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS (Businesswire)
12.12.19		plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer (Businesswire)
12.12.19		GILD's KTE-X19 To Face FDA, NTEC Drops As NVS Walks Away, KZIA On Watch (RTTNews)
12.12.19		Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium (Businesswire)
02.12.19		Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries (Businesswire)
06.11.19		Puma Biotechnology Reports Third Quarter 2019 Financial Results (Businesswire)
04.11.19		Puma Biotechnology to Present at the Credit Suisse Healthcare Conference (Businesswire)
23.10.19		Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Businesswire)
03.10.19		Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
02.10.19		FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer (Businesswire)
25.09.19		Puma Biotechnology to Present at Cantor Global Healthcare Conference (Businesswire)
11.09.19		Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

US-Rezession: Bitcoin-Kurs vor Sprung?

Milliardenauftrag: Apple setzt auf NVIDIA-KI-Technologie

Terrific 10 statt Magnificent 7: Top-Tech-Aktien aus China für 2025 die bessere Wahl?

Diese Aktien empfehlen Experten zu kaufen

Gaspreis, Goldpreis, Ölpreis & Co aktuell

Bitcoin Kurs Prognose: 1 Million in 12 Monaten trotz hoher Verluste?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	08.04.2025 10:57
Kaufwert:	EUR
	Hinzufügen Speichern

Puma Biotechnology Aktie

WKN DE: A1J643 / ISIN: US74587V1070

Nachrichten zu Puma Biotechnology Inc

Newssuche

Meistgelesene Nachrichten